StocksA › ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR) — Earnings Call X-Ray

Our AI read all 39 of ARWR's earnings calls (2015–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q2 2025 · sign up to see
Previous Call Grade
D
Q1 2025
Expected Move
🔒
next 45 days · members
Calls Analyzed
39
2015–2025
Avg Candor
6.7/9
evasion 4/9
Critic AmmunitionFounder-LedDeferred Revenue GrowingUnderused Fixed CostsMargins ContractingCapex IncreasingReads RehearsedQuestion Left Hanging

Call-by-call analysis

🔒 Q2 2025 earnings call 2025-05-12 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q2 2025 call grade is ready
The full 37-point AI read of ARWR's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

D Q1 2025 earnings call 2025-02-10 move ±14.8%

Management gave no formal guidance against contracting margins. The delivery was rich in specifics.

Margins: contractingHeadcount: growingCapex: increasing 11 analysts · 16 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Prepayments growing⚑ Reads rehearsed
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 7/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
YES Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C+ Q4 2024 earnings call 2024-11-26 move ±32.5%

Management held guidance steady against accelerating demand and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: acceleratingMargins: contractingHeadcount: growingCapex: increasing 13 analysts · 17 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Prepayments growing
Candor 7/9
Specificity 8/9
Evasion 4/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
YES Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
YES Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C Q3 2024 earnings call 2024-08-08 move ±17.3%

Management held guidance steady against accelerating demand and contracting margins. The delivery was rich in specifics, promotional in tone.

Guidance: maintainedDemand: acceleratingMargins: contractingHeadcount: growingCapex: decreasing 9 analysts · 19 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 8/9
Uncertainty 4/9
Promotion 7/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C Q2 2024 earnings call 2024-05-09 move ±18.8%

Management gave no formal guidance against contracting margins. The delivery was unusually candid, rich in specifics.

Margins: contractingHeadcount: growingCapex: decreasing 8 analysts · 15 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedFounder-ledDirection beats results
Candor 7/9
Specificity 8/9
Evasion 3/9
Confidence 8/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank
1 more research questions answered NO

D Q1 2024 earnings call 2024-02-06 move ±14.6%

Management lowered guidance against steady demand and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: loweredDemand: stableMargins: contractingHeadcount: flatCapex: decreasing 13 analysts · 23 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubtsFounder-ledDirection beats results
Candor 7/9
Specificity 8/9
Evasion 4/9
Confidence 8/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C+ Q4 2023 earnings call 2023-11-29 move ±33.5%

Management gave no formal guidance against contracting margins. The delivery was unusually candid, rich in specifics, promotional in tone.

Margins: contractingCapex: increasing 11 analysts · 14 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedFounder-led
Candor 7/9
Specificity 8/9
Evasion 3/9
Confidence 8/9
Uncertainty 4/9
Promotion 7/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C Q3 2023 earnings call 2023-08-07 move ±16.8%

Management gave no formal guidance against steady demand and contracting margins. The delivery was rich in specifics.

Demand: stableMargins: contractingCapex: increasing 11 analysts · 22 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedFounder-led
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 8/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q2 2023 2023-05-02 C noneacceleratingunclear 7/9 3/9
Q1 2023 2023-02-06 D maintainedunclearcontracting 7/9 5/9
Q4 2022 2022-11-28 D maintainedacceleratingunclear 7/9 5/9
Q3 2022 2022-08-04 C noneunclearcontracting 7/9 5/9
Q2 2022 2022-05-10 D loweredunclearunclear 7/9 5/9
Q1 2022 2022-02-02 C maintainedstablecontracting 7/9 4/9
Q4 2021 2021-11-22 C nonestableunclear 7/9 5/9
Q3 2021 2021-08-06 D nonestableunclear 7/9 5/9
Q2 2021 2021-05-05 D noneacceleratingunclear 6/9 5/9
Q1 2021 2021-02-04 D noneunclearcontracting 7/9 4/9
Q4 2020 2020-11-23 F noneunclearcontracting 6/9 7/9
Q3 2020 2020-08-05 C+ noneunclearcontracting 7/9 3/9
Q2 2020 2020-05-08 C+ maintainedstablecontracting 7/9 3/9
Q1 2020 2020-02-05 C noneacceleratingunclear 7/9 2/9
Q4 2019 2019-11-26 C noneunclearunclear 7/9 5/9
Q3 2019 2019-08-05 D maintainedunclearunclear 7/9 3/9
Q2 2019 2019-05-08 B maintainedunclearcontracting 7/9 2/9
Q1 2019 2019-02-08 D maintainedacceleratingunclear 6/9 5/9
Q4 2018 2018-12-11 B noneacceleratingunclear 7/9 2/9
Q3 2018 2018-08-07 C maintainedacceleratingunclear 7/9 4/9
Q2 2018 2018-05-08 C noneunclearcontracting 7/9 2/9
Q1 2018 2018-02-09 D maintainedunclearcontracting 6/9 5/9
Q4 2017 2017-12-13 F noneunclearcontracting 7/9 4/9
Q3 2017 2017-08-03 D noneunclearexpanding 6/9 2/9
Q2 2017 2017-05-03 D noneunclearcontracting 6/9 4/9
Q1 2017 2017-02-06 F noneunclearunclear 7/9 6/9
Q4 2016 2016-12-14 F withdrawnunclearcontracting 7/9 7/9
Q3 2016 2016-08-09 D noneunclearcontracting 7/9 3/9
Q2 2016 2016-05-11 C noneunclearcontracting 6/9 4/9
Q1 2016 2016-02-09 F noneunclearunclear 6/9 5/9
Q4 2015 2015-12-14 D noneunclearcontracting 6/9 4/9

Research question bank — earlier calls

During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of ARWR's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.

D Q4 2022 earnings call 2022-11-28

310 more research questions answered NO

C Q3 2022 earnings call 2022-08-04

1 more research questions answered NO

F Q4 2017 earnings call 2017-12-13

1 more research questions answered NO

D Q3 2016 earnings call 2016-08-09

1 more research questions answered NO

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAC · AAC Holdings'AACAY · AAC Technologies HoldingAACG · ATA Creativity GlobalAADI · Aadi Bioscience, Inc.AALBF · Aalberts N.V.AAOI · Applied Optoelectronics,

ARW   All “A” companies    ARZGF

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.